Global Information
회사소개 | 문의

부정맥 : 파이프라인 리뷰

Arrhythmias - Pipeline Review, H2 2018

리서치사 Global Markets Direct
발행일 2018년 08월 상품 코드 219844
페이지 정보 영문 52 Pages
가격
US $ 2,000 ₩ 2,272,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,545,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,818,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


부정맥 : 파이프라인 리뷰 Arrhythmias - Pipeline Review, H2 2018
발행일 : 2018년 08월 페이지 정보 : 영문 52 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

부정맥은 심박 속도 또는 리듬의 장애입니다. 부정맥이 일어나고 있는 동안 심장 고동은 매우 빠르거나 매우 늦거나 불규칙한 리듬입니다. 징후 또는 증상에는 불안, 허약, 현기증 및 어지러움, 실신, 발한, 호흡곤란 및 흉통 등이 있습니다. 치료에는 항부정맥약 및 항응고제 등이 이용됩니다.

세계의 부정맥 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발·출시의 최신 동향, 임상시험 각 단계의 제품, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등의 정보를 정리하여 전해드립니다.

목차

서론

  • 분석 범위

부정맥 개요

치료제 개발

  • 부정맥용 파이프라인 제품 : 개요
  • 부정맥용 파이프라인 제품 : 비교 분석

부정맥 : 각 기업에서 개발중인 치료제

부정맥 : 대학/연구기관에서 연구중인 치료제

부정맥 : 파이프라인 제품 개요

  • 임상시험 단계 제품
  • 초기 단계 제품

부정맥 : 개발중인 제품(기업별)

부정맥 : 연구중인 제품(대학/연구기관별)

부정맥 개발에 참여하고 있는 기업

  • Cynata Therapeutics Limited
  • Gilead Sciences, Inc.
  • Ono Pharmaceutical Co., Ltd.
  • Orion Oyj
  • SciFluor Life Sciences, LLC
  • SignPath Pharma Inc

부정맥 : 치료제 평가

  • 단일요법의 경우
  • 표적별
  • 작용기서별
  • 투여 방법별
  • 분자 종류별

약제 개요

  • aladorian sodium
    • 제품 개요
    • 기능 메커니즘
    • 연구개발(R&D)의 진전 상황
  • QT 연장 증후군용 hERG1 활성 안티센스 올리고뉴클레오티드
  • efsevin
  • eleclazine
  • EU-8120
  • GS-967
  • KN-93
  • landiolol
  • LH-021
  • ORM-10103
  • PP-1
  • 부정맥용 소분자
  • 심실성 부정맥용 리아노딘 수용체 2길항제
  • 부정맥·심부전용 CaMKII 저해제
  • 순환기계 질환용 줄기세포 요법
  • VKII-86

부정맥 : 파이프라인 제품의 최신 동향

부정맥 : 개발 휴지 상태의 제품

부정맥 : 개발이 중지된 제품

부정맥 관련 제품 개발 마일스톤

  • 주목 최신 동향·프레스 릴리스

부록

도표

KSA 16.04.28

List of Tables

  • Number of Products under Development for Arrhythmias, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Stage and Target, H2 2018
  • Number of Products by Stage and Mechanism of Action, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Arrhythmias - Pipeline by Cynata Therapeutics Ltd, H2 2018
  • Arrhythmias - Pipeline by Gilead Sciences Inc, H2 2018
  • Arrhythmias - Pipeline by LATITUDE Pharmaceuticals Inc, H2 2018
  • Arrhythmias - Pipeline by Les Laboratoires Servier SAS, H2 2018
  • Arrhythmias - Pipeline by OMEICOS Therapeutics GmbH, H2 2018
  • Arrhythmias - Pipeline by Ono Pharmaceutical Co Ltd, H2 2018
  • Arrhythmias - Pipeline by Orion Corporation, H2 2018
  • Arrhythmias - Pipeline by SignPath Pharma Inc, H2 2018
  • Arrhythmias - Dormant Projects, H2 2018
  • Arrhythmias - Discontinued Products, H2 2018

List of Figures

  • Number of Products under Development for Arrhythmias, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Top 10 Targets, H2 2018
  • Number of Products by Stage and Top 10 Targets, H2 2018
  • Number of Products by Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Routes of Administration, H2 2018
  • Number of Products by Stage and Routes of Administration, H2 2018
  • Number of Products by Molecule Types, H2 2018
  • Number of Products by Stage and Molecule Types, H2 2018

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Arrhythmias - Pipeline Review, H2 2018, provides an overview of the Arrhythmias (Cardiovascular) pipeline landscape.

An arrhythmia is a problem with the rate or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. Signs and symptoms include anxiety, weakness, dizziness, and light-headedness, fainting or nearly fainting, sweating, shortness of breath and chest pain. Treatment includes anti-arrhythmics and anticoagulants.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Arrhythmias - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Arrhythmias (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Arrhythmias (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Arrhythmias and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 9 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Arrhythmias (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Arrhythmias (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Arrhythmias (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Arrhythmias (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Arrhythmias (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Arrhythmias (Cardiovascular)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Arrhythmias (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Arrhythmias (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Arrhythmias - Overview
    • Arrhythmias - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Arrhythmias - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Arrhythmias - Companies Involved in Therapeutics Development
    • Cynata Therapeutics Ltd
    • Gilead Sciences Inc
    • LATITUDE Pharmaceuticals Inc
    • Les Laboratoires Servier SAS
    • OMEICOS Therapeutics GmbH
    • Ono Pharmaceutical Co Ltd
    • Orion Corporation
    • SignPath Pharma Inc
  • Arrhythmias - Drug Profiles
    • amiodarone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense Oligonucleotides to Activate hERG1 for Arrhythmias - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • efsevin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EU-8120 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GS-680 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GS-967 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KN-93 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • landiolol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • M-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OMT-28 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ORM-10103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PAM-4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PP-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize RyR2 for Heart Failure and Arrhythmias - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Target FKBP1A for Cardiovascular Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SPP-4040 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Asthma and Cardiovacular Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Arrhythmias - Dormant Projects
  • Arrhythmias - Discontinued Products
  • Arrhythmias - Product Development Milestones
    • Featured News & Press Releases
      • Sep 27, 2017: U.S. Patent Granted for Cynata Cymerus Technology
      • Sep 05, 2017: Cynata to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York
      • Apr 19, 2017: Cynata Advances to Pre-IND Meeting with US FDA
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top
전화 문의
이용안내
 
BCC Research